Vividion Therapeutics

Vividion’s chemoproteomics platform turns new chemistry into maps of the druggable proteome. With Vividion scientists the lab has built enantiocontrolled azetidine libraries and complete sets of saturated-heterocycle stereoprobes for chemoproteomic discovery.

San Diego, California · A Bayer company since 2021

Papers together
2
Years
2025–present
Co-authors
18
The record

All 2 papers with Vividion Therapeutics

All partners →
  1. Radical Cross-Coupling Delivers Complete Sets of Saturated-Heterocyclic Regio- and Stereoprobes for Chemoproteomic Discovery

    ChemRxiv 2026Preprint · doi:10.26434/chemrxiv.15010428/v1 · In our publications

    • Vividion Therapeutics Ann Shih, Annabel Q. Ansel, Benjamin D. Horning, Brian E. Nordin, Brian N. Cook, Christie L. Eissler, Christopher A. Toth, Cian Kingston, Cody L. Fullenwider, Connor Scheuerman, David S. Weinstein, Gabriel M. Simon, Jonathan Pollock, Matthew P. Patricelli, Steffen M. Bernard, Steven C Wang, Tracey Nguyen

Our co-authors at Vividion Therapeutics

Annabel Q. AnselSteffen M. BernardBrian N. CookBenjamin F. CravattChristie L. EisslerCody L. FullenwiderBenjamin D. HorningCian KingstonTracey NguyenBrian E. NordinMatthew P. PatricelliJonathan PollockConnor ScheuermanAnn ShihGabriel M. SimonChristopher A. TothSteven C WangDavid S. Weinstein

Work with us

Interested in collaborating with the Baran lab?

If your team has a problem that matters, a molecule no one can make, a reaction that will not scale, a reagent that should exist, we would love to hear about it.

Email Phil

or write to pbaran@scripps.edu